Ann: Appendix 4C and Quarterly Activity Report, page-7

The overhead that AN1 carried is way too much for the Evolis turnover.
While Evolis deliveries are prompt, its hard getting them in.
The HNG acknowledges the problem, let's see how they are managed, maybe as you point out its under BL.
Have you seen any of those new products hit the market, like eyelash treatments?

My view, they have acquired that line from BWX, so there is dialogue behind the scenes. BWX sales are around $230m but are in real trouble, their debt after restructure will be $93M, looking at their numbers I can't see them turning a net profit with that debt level. Maybe some more opportunity here!